ReviewPathogens (Basel, Switzerland)2016
Adhesive Pili in UTI Pathogenesis and Drug Development.
Review in Pathogens (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis.American journal of obstetrics and gynecology · 2020Pooled it
- Parallel evolutionary trajectories rewire enteropathogenicGut microbes · 2026Article
- First Randomized Controlled Trial Comparing D-Mannose to Fosfomycin in Acute Uncomplicated Lower Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Distribution of Uropathogens and Molecular Characterisation of Virulence Genes of UropathogenicPathogens (Basel, Switzerland) · 2026Article
- RstAB activates type 1 fimbriae to promote uropathogeniciScience · 2026Article
- Whole-proteome structure/function prediction in UropathogenicbioRxiv : the preprint server for biology · 2026Article
- Uropathogenic Escherichia coli invade luminal prostate cells via FimH-PPAP receptor binding.Nature microbiology · 2026Article
- Unraveling the Nutritional Perspectives of Probiotics and Prebiotics in Female Healthcare.Recent advances in food, nutrition & agriculture · 2026Review
- CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025Review
- Analysis of phylogroups, biofilm formation, virulence factors, antibiotic resistance and molecular typing of uropathogenic Escherichia coli strains isolated from patients with recurrent and non-recurrent urinary tract infections.BMC infectious diseases · 2025Article
- Mechanisms of uropathogenicScience advances · 2025Article
- Biogenic amine tryptamine in human vaginal probiotic isolates mediates matrix inhibition and thwarts uropathogenic E. coli biofilm.Scientific reports · 2024Article
- The Role of Metabolomics and Microbiology in Urinary Tract Infection.International journal of molecular sciences · 2024Review
- Tamm-Horsfall protein in humane urine: sex-dependent differences in the excretion and N-glycosylation pattern.Scientific reports · 2023Article
- Urinary Tract Infections Caused by UropathogenicInternational journal of molecular sciences · 2023Review
- Designed α-sheet peptides disrupt uropathogenic E. coli biofilms rendering bacteria susceptible to antibiotics and immune cells.Scientific reports · 2023Article
- FimH and Type 1 Pili Mediated Tumor Cell Cytotoxicity by UropathogenicPathogens (Basel, Switzerland) · 2023Article
- Natural Polyphenols for Prevention and Treatment of Urinary Tract Infections.International journal of molecular sciences · 2023Review
- The Diversity ofMicroorganisms · 2023Review
- In Vivo Role of Two-Component Regulatory Systems in Models of Urinary Tract Infections.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Urinary tract infections (UTIs) are one of the most common bacterial infections, affecting 150 million people each year worldwide. High recurrence rates and increasing antimicrobial resistance among uropathogens are making it imperative to develop alternative strategies for the treatment and prevention of this common infection. In this Review, we discuss how understanding the: (i) molecular and biophysical basis of host-pathogen interactions; (ii) consequences of the molecular cross-talk at the host pathogen interface in terms of disease progression; and (iii) pathophysiology of UTIs is leading to efforts to translate this knowledge into novel therapeutics to treat and prevent these infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.